A retrospective study of amrubicin monotherapy in the treatment of relapse after first-line treatment with ICI (arm A) and to investigate the efficacy of amrubicin therapy after arm A compared with after chemotherapy without ICI (arm B)
Latest Information Update: 28 Jul 2021
At a glance
- Drugs Amrubicin (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 28 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology